Related Experiment Video
Updated: May 20, 2025
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Treatment strategies for advanced synovial sarcoma: from chemotherapy to TCR-engineered T-cell therapy
Tomoki Nakamura1, Masahiro Hasegawa2
1Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. tomoki66@med.mie-u.ac.jp.
Abstract:
Synovial sarcoma (SS) is the most common soft tissue sarcoma in children and adolescents. Despite the availability of new agents such as pazopanib and trabectedin, the prognosis after recurrence remains poor. Adoptive cell therapy is an emerging therapeutic strategy based on the modulation, manipulation, and selection of autologous T-cells in vitro to overcome immune system tolerance to tumor cells. Cancer-testis antigens are particularly attractive targets for immune therapy because male germ cells lack human leukocyte antigen class I molecules, limiting T-cell responses triggered by antigen presentation. T-cell receptor (TCR) engineered T-cell therapy targeting NY-ESO-1 and MAGE-A4 holds significant promise because of the high positive expression of these antigens in tumors. This approach facilitates the reprogramming of T lymphocytes by a transgenic TCR through gene transfer of TCR α and β chains specific to tumor antigens, offering potential therapeutic advances for patients with advanced SS. Clinical trials of TCR-engineered T-cell therapy targeting NY-ESO-1 and MAGE-A4 have been conducted, with an objective response rate reported to be 40-60% across several trials. This promising efficacy suggests that TCR-engineered T-cell therapy could become an attractive novel therapeutic option for advanced SS, which has limited treatment options in later stages. However, if TCR-engineered T-cell therapy is to be used in clinical practice, the standard approach following the failure of doxorubicin-based chemotherapy in patients with advanced SS must be defined. Future studies will be critical for establishing treatment strategies in this field.
Insights
T-cell receptor (TCR) engineered T-cell therapy targeting cancer-testis antigens shows promise for advanced synovial sarcoma (SS). This approach offers a potential new treatment option for patients with poor prognosis after recurrence.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Synovial sarcoma (SS) is a prevalent soft tissue sarcoma in pediatric and adolescent populations.
- Recurrent SS has a poor prognosis, with limited effective treatment options beyond standard chemotherapy.
- Adoptive cell therapy, particularly T-cell receptor (TCR) engineered T-cell therapy, is an emerging strategy to overcome tumor immune tolerance.
Purpose of the Study:
- To evaluate the potential of TCR engineered T-cell therapy targeting cancer-testis antigens (NY-ESO-1 and MAGE-A4) as a novel treatment for advanced synovial sarcoma.
- To highlight the promise of this approach given the high expression of these antigens in SS tumors and the limitations of existing therapies.
Main Methods:
- Gene transfer of TCR alpha and beta chains specific to tumor antigens (NY-ESO-1, MAGE-A4) into autologous T-cells.
- In vitro modulation, manipulation, and selection of T-cells to enhance anti-tumor responses.
- Clinical trials assessing the efficacy and safety of TCR engineered T-cell therapy in patients with advanced SS.
Main Results:
- Clinical trials involving TCR engineered T-cell therapy targeting NY-ESO-1 and MAGE-A4 have demonstrated significant promise.
- Objective response rates ranging from 40-60% have been reported across several trials, indicating therapeutic potential.
- This approach leverages cancer-testis antigens, which are attractive targets due to restricted expression in normal tissues and potential for T-cell activation.
Conclusions:
- TCR engineered T-cell therapy targeting NY-ESO-1 and MAGE-A4 represents a promising novel therapeutic option for advanced synovial sarcoma.
- Further research is critical to define the optimal clinical application and standard treatment protocols, especially after chemotherapy failure.
- Establishing clear treatment pathways will be essential for integrating this innovative therapy into clinical practice for advanced SS.
More Related Videos
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...